Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.

Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, Bours V, Jerusalem G.

BMC Cancer. 2018 Jan 29;18(1):102. doi: 10.1186/s12885-018-4015-4.

2.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M.

Breast. 2018 Apr;38:144-149. doi: 10.1016/j.breast.2017.12.016. Epub 2018 Jan 8.

PMID:
29324303
3.

Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers.

Latgé G, Poulet C, Bours V, Josse C, Jerusalem G.

Int J Mol Sci. 2018 Jan 2;19(1). pii: E123. doi: 10.3390/ijms19010123. Review.

4.

Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer.

Wenric S, ElGuendi S, Caberg JH, Bezzaou W, Fasquelle C, Charloteaux B, Karim L, Hennuy B, Frères P, Collignon J, Boukerroucha M, Schroeder H, Olivier F, Jossa V, Jerusalem G, Josse C, Bours V.

Sci Rep. 2017 Dec 12;7(1):17452. doi: 10.1038/s41598-017-17811-2.

5.

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.

Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group.

Ann Oncol. 2018 Mar 1;29(3):661-668. doi: 10.1093/annonc/mdx772.

PMID:
29228091
6.

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C.

Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.

PMID:
29198055
7.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
8.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

9.

Communication of healthcare professionals: Is there ageism?

Schroyen S, Adam S, Marquet M, Jerusalem G, Thiel S, Giraudet AL, Missotten P.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12780. Epub 2017 Sep 27.

PMID:
28960583
10.

Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.

Grégoire C, Bragard I, Jerusalem G, Etienne AM, Coucke P, Dupuis G, Lanctôt D, Faymonville ME.

Br J Cancer. 2017 Nov 7;117(10):1442-1449. doi: 10.1038/bjc.2017.326. Epub 2017 Sep 19.

PMID:
28926526
11.

Association between self-perception of aging, view of cancer and health of older patients in oncology: a one-year longitudinal study.

Schroyen S, Missotten P, Jerusalem G, Van den Akker M, Buntinx F, Adam S.

BMC Cancer. 2017 Sep 2;17(1):614. doi: 10.1186/s12885-017-3607-8.

12.

Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.

Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD; ESC Cardiac Oncology Toxicity Long-Term Registry Investigators.

ESC Heart Fail. 2017 Aug;4(3):312-318. doi: 10.1002/ehf2.12162. Epub 2017 May 2.

13.

[Carcinoma of unknown primary : a not so rare entity].

Gonne E, Collignon J, Jerusalem G, Gennigens C.

Rev Med Liege. 2016 Oct;71(10):449-454. Review. French.

14.

[Cancer therapy-induced cardiotoxicity].

Frères P, Poncin A, Moonen M, Josse C, Oury C, Bours V, Lancellotti P, Jerusalem G.

Rev Med Liege. 2016 Sep;71(9):382-387. Review. French.

15.

Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life.

Leclerc AF, Foidart-Dessalle M, Tomasella M, Coucke P, Devos M, Bruyère O, Bury T, Deflandre D, Jerusalem G, Lifrange E, Kaux JF, Crielaard JM, Maquet D.

Eur J Phys Rehabil Med. 2017 Oct;53(5):633-642. doi: 10.23736/S1973-9087.17.04551-8. Epub 2017 Mar 20.

16.

A Nonrandomized Comparison Study of Self-Hypnosis, Yoga, and Cognitive-Behavioral Therapy to Reduce Emotional Distress in Breast Cancer Patients.

Bragard I, Etienne AM, Faymonville ME, Coucke P, Lifrange E, Schroeder H, Wagener A, Dupuis G, Jerusalem G.

Int J Clin Exp Hypn. 2017 Apr-Jun;65(2):189-209. doi: 10.1080/00207144.2017.1276363.

PMID:
28230462
17.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.

Noguchi S, Shinohara N, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J, Bouillaud E, Fan J, Nonomura N.

Oncology. 2017;92(5):243-254. doi: 10.1159/000457904. Epub 2017 Feb 21.

PMID:
28219073
18.

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.

Yip C, Foidart P, Somja J, Truong A, Lienard M, Feyereisen E, Schroeder H, Gofflot S, Donneau AF, Collignon J, Delvenne P, Sounni NE, Jerusalem G, Noël A.

Br J Cancer. 2017 Mar 14;116(6):742-751. doi: 10.1038/bjc.2017.23. Epub 2017 Feb 14.

19.

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.

Lousberg L, Jerusalem G.

Breast Cancer (Auckl). 2017 Jan 4;10:239-252. doi: 10.4137/BCBCR.S12443. eCollection 2016. Review.

20.

Multidisciplinary management of breast cancer.

Leclerc AF, Jerusalem G, Devos M, Crielaard JM, Maquet D.

Arch Public Health. 2016 Dec 5;74:50. eCollection 2016.

21.
22.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.

Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10.

PMID:
27745744
23.

The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study.

Schroyen S, Marquet M, Jerusalem G, Dardenne B, Van den Akker M, Buntinx F, Adam S, Missotten P.

J Geriatr Oncol. 2017 Jan;8(1):64-68. doi: 10.1016/j.jgo.2016.09.001. Epub 2016 Sep 19.

PMID:
27659547
24.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29.

PMID:
27358383
25.

Triple-negative breast cancer: treatment challenges and solutions.

Collignon J, Lousberg L, Schroeder H, Jerusalem G.

Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.

26.

Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells.

Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, Skrypek N, Thompson EW, Jérusalem G, Berx G, Thiry M, Blacher S, Hollier BG, Noël A, Oury C, Polette M, Gilles C.

Cancer Res. 2016 Jul 15;76(14):4270-82. doi: 10.1158/0008-5472.CAN-15-2263. Epub 2016 May 24.

27.

Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging.

Lancellotti P, Moonen M, Jerusalem G.

Echocardiography. 2016 Apr;33(4):504-9. doi: 10.1111/echo.13187. No abstract available.

PMID:
27103482
28.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D.

J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18.

PMID:
27091708
29.

Corrigendum to "Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicenter prospective study" [J. Geriatr. Oncol. 6 (2015) 401-410].

Baitar A, Kenis C, Moor R, Decoster L, Luce S, Bron D, Van Rijswijk R, Rasschaert M, Langenaeken C, Jerusalem G, Lobelle JP, Flamaing J, Milisen K, Wildiers H.

J Geriatr Oncol. 2016 Mar;7(2):142-3. doi: 10.1016/j.jgo.2016.01.005. Epub 2016 Feb 8.

PMID:
27037160
30.

[Biopsy of suspicious lesions in patients with breast cancer].

Colin PE, Schroeder H, Gonne E, Hanocq F, André C, Rorive A, Jerusalem G, Collignon J.

Rev Med Liege. 2015 Nov;70(11):563-8. French.

31.

Circulating microRNA-based screening tool for breast cancer.

Frères P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H, Kridelka F, Lifrange E, Jossa V, Bours V, Josse C, Jerusalem G.

Oncotarget. 2016 Feb 2;7(5):5416-28. doi: 10.18632/oncotarget.6786.

32.

A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators.

Kenis C, Heeren P, Decoster L, Van Puyvelde K, Conings G, Cornelis F, Cornette P, Moor R, Luce S, Libert Y, Van Rijswijk R, Jerusalem G, Rasschaert M, Langenaeken C, Baitar A, Specenier P, Geboers K, Vandenborre K, Debruyne PR, Vanoverbeke K, Van den Bulck H, Praet JP, Focan C, Verschaeve V, Nols N, Goeminne JC, Petit B, Lobelle JP, Flamaing J, Milisen K, Wildiers H.

J Nutr Health Aging. 2016 Jan;20(1):60-70. doi: 10.1007/s12603-015-0538-4.

PMID:
26728935
33.

Ageism and caring attitudes among nurses in oncology.

Schroyen S, Missotten P, Jerusalem G, Gilles C, Adam S.

Int Psychogeriatr. 2016 May;28(5):749-57. doi: 10.1017/S1041610215001970. Epub 2015 Dec 16.

PMID:
26669734
34.

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.

Jerusalem G, Neven P, Marinsek N, Zhang J, Degun R, Benelli G, Saletan S, Ricci JF, Andre F.

BMC Cancer. 2015 Oct 24;15:787. doi: 10.1186/s12885-015-1762-3.

35.

Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.

Boukerroucha M, Josse C, ElGuendi S, Boujemla B, Frères P, Marée R, Wenric S, Segers K, Collignon J, Jerusalem G, Bours V.

BMC Cancer. 2015 Oct 21;15:755. doi: 10.1186/s12885-015-1740-9.

36.

The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment.

Jerusalem G, Moonen M, Freres P, Lancellotti P.

Future Oncol. 2015;11(20):2791-4. doi: 10.2217/fon.15.227. Epub 2015 Sep 7. No abstract available.

37.

Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer.

Maris P, Blomme A, Palacios AP, Costanza B, Bellahcène A, Bianchi E, Gofflot S, Drion P, Trombino GE, Di Valentin E, Cusumano PG, Maweja S, Jerusalem G, Delvenne P, Lifrange E, Castronovo V, Turtoi A.

PLoS Med. 2015 Sep 1;12(9):e1001871. doi: 10.1371/journal.pmed.1001871. eCollection 2015 Sep.

38.

Mesenchymal Stem Cells Shed Amphiregulin at the Surface of Lung Carcinoma Cells in a Juxtacrine Manner.

Carnet O, Lecomte J, Masset A, Primac I, Durré T, Maertens L, Detry B, Blacher S, Gilles C, Péqueux C, Paupert J, Foidart JM, Jerusalem G, Cataldo D, Noel A.

Neoplasia. 2015 Jul;17(7):552-63. doi: 10.1016/j.neo.2015.07.002.

39.

Implementation of geriatric assessment-based recommendations in older patients with cancer: A multicentre prospective study.

Baitar A, Kenis C, Moor R, Decoster L, Luce S, Bron D, Van Rijswijk R, Rasschaert M, Langenaeken C, Jerusalem G, Lobelle JP, Flamaing J, Milisen K, Wildiers H.

J Geriatr Oncol. 2015 Sep;6(5):401-10. doi: 10.1016/j.jgo.2015.07.005. Epub 2015 Aug 18. Erratum in: J Geriatr Oncol. 2016 Mar;7(2):142-3.

PMID:
26296908
40.

[BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].

Jerusalem G, Collignon J, Josse C, Schroeder H, Rorive A, Frères P, Lambert F, Koopmansch B, Poncin A, Bours V.

Rev Med Liege. 2015 May-Jun;70(5-6):269-76. Review. French.

41.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.

Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.

Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.

PMID:
26242220
42.

Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.

Jerusalem G, Rorive A, Collignon J.

Future Oncol. 2015;11(12):1775-89. doi: 10.2217/fon.15.80. Review.

43.

[Management of febrile neutropenia in cancer patients].

Freres P, Gonne E, Collignon J, Giot JB, Gennigens C, Jerusalem G.

Rev Med Liege. 2015 Apr;70(4):195-200. Review. French.

44.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.

PMID:
26044370
45.

Oncological and surgical outcome after oncoplastic breast surgery.

Nizet JL, Maweja S, Lakosi F, Lifrange E, Scagnol I, Seidel L, Albert A, Jerusalem G.

Acta Chir Belg. 2015 Jan-Feb;115:33-41.

PMID:
26021789
46.

BRCA1 germline mutation and glioblastoma development: report of cases.

Boukerroucha M, Josse C, Segers K, El-Guendi S, Frères P, Jerusalem G, Bours V.

BMC Cancer. 2015 Mar 26;15:181. doi: 10.1186/s12885-015-1205-1.

47.

Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer.

Bovy N, Blomme B, Frères P, Dederen S, Nivelles O, Lion M, Carnet O, Martial JA, Noël A, Thiry M, Jérusalem G, Josse C, Bours V, Tabruyn SP, Struman I.

Oncotarget. 2015 Apr 30;6(12):10253-66.

48.

[The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].

Jerusalem G, Rorive A, Collignon J.

Rev Med Liege. 2014 Sep;69(9):510-7. Review. French.

49.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ.

Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.

PMID:
25747197
50.

EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.

Lancellotti P, Anker SD, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Maggioni AP, Jerusalem G, Galderisi M.

Eur Heart J Cardiovasc Imaging. 2015 May;16(5):466-70. doi: 10.1093/ehjci/jev024. Epub 2015 Mar 4. Review.

PMID:
25744342

Supplemental Content

Loading ...
Support Center